Exeantide in Type 2 Diabetes on Insulin

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.

Key facts

Study ID
NCT01154933
Run by
University at Buffalo
People needed
24
Starts
2008-04-01
Expected to finish
2011-11-01
Last updated by the study team
2022-10-06

Who can join

Age: 20 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.